Current Status on 1,4-Dihydropyridine Derivatives against Human Pathogenic Parasites.

Dihydropyridine chemotherapy leishmaniasis malaria parasitic diseases trypanosomiasis

Journal

Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157

Informations de publication

Date de publication:
2023
Historique:
received: 15 06 2022
revised: 18 08 2022
accepted: 20 09 2022
pubmed: 7 11 2022
medline: 17 3 2023
entrez: 6 11 2022
Statut: ppublish

Résumé

Infections provoked by parasites are among the most prevalent diseases worldwide and generate important health and socioeconomic problems. Despite the enormous amount of work done, the chemotherapy for most of them remains unsolved. Usually, treatments are based on no specific drugs associated, in several cases, with long-term treatments and severe side effects. In addition, drug resistance and different strains' susceptibility are further drawbacks of the existing chemotherapy. Considering that 1,4-dihydropyridines derivatives constitute an important class of compounds for new drug development, we present in this review an in-depth overview of the work done so far on 1,4-dihydropyridines and their antiparasitic activities. The development of new derivatives or the application of known drugs used for other diseases is described in terms of their potential usefulness for drug design.

Identifiants

pubmed: 36336811
pii: CMC-EPUB-127415
doi: 10.2174/0929867330666221104162901
doi:

Substances chimiques

1,4-dihydropyridine 7M8K3P6I89
Dihydropyridines 0
Antiparasitic Agents 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1689-1711

Subventions

Organisme : University of Buenos Aires
ID : 20020170100167BA
Organisme : National Research Council of Argentina
ID : PIP 11220170100420CO

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Orlando Elso (O)

Cátedra de Farmacognosia, IQUIMEFA (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 954, C1113AAD, Buenos Aires, Argentina.
Laboratorio de Biocatálisis, Departamento de Química Orgánica y UMYMFOR, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, piso 3, C1428EGA, Buenos Aires, Argentina.

Guadalupe García Liñares (GG)

Laboratorio de Biocatálisis, Departamento de Química Orgánica y UMYMFOR, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, piso 3, C1428EGA, Buenos Aires, Argentina.

Valeria Sülsen (V)

Cátedra de Farmacognosia, IQUIMEFA (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 954, C1113AAD, Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH